B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

13.55 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 13.55
Bid (Size) 5.440 (1)
Ask (Size) 15.00 (1)
Prev. Close 13.55
Today's Range 13.55 - 13.55
52wk Range 5.200 - 14.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via Globe NewsWire
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via Globe NewsWire

Performance

YTD
+35.36%
+35.36%
1 Month
+2.65%
+2.65%
3 Month
+63.25%
+63.25%
6 Month
+76.89%
+76.89%
1 Year
+21.09%
+21.09%

More News

Read More
Earnings Scheduled For March 1, 2023
Via Benzinga
uniQure Stock Trying To Close In On Key Technical Measure
Via Investor's Business Daily
Why Shares of Alvotech Jumped This Week
Via The Motley Fool
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via Globe NewsWire
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via Globe NewsWire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via Globe NewsWire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via Globe NewsWire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via Globe NewsWire
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via Globe NewsWire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via Globe NewsWire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via Globe NewsWire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via Globe NewsWire
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via Globe NewsWire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via Globe NewsWire
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via Globe NewsWire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via Globe NewsWire
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.